Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C13H22N4O3S.ClH |
| Molecular Weight | 350.8663 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CNC(=CN(=O)=O)NCCSCc1ccc(CN(C)C)o1.Cl
InChI
InChIKey=GGWBHVILAJZWKJ-UHFFFAOYSA-N
InChI=1S/C13H22N4O3S.ClH/c1-14-13(9-17(18)19)15-6-7-21-10-12-5-4-11(20-12)8-16(2)3;/h4-5,9,14-15H,6-8,10H2,1-3H3;1H
| Molecular Formula | ClH |
| Molecular Weight | 36.4609 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C13H22N4O3S |
| Molecular Weight | 314.4054 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
CNS Activity
Curator's Comment:: Ranitidine, when given in conventional doses, can cause adverse central nervous system reactions (CNS-ADRs), particularly in older patients who have substantial renal function impairment. These CNS-ADRs occur as a consequence of altered ranitidine disposition. Ranitidine doses should be reduced when renal function impairment is present, and patients should be carefully observed for CNS-ADRs.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: P25102 Gene ID: 25461.0 Gene Symbol: Hrh2 Target Organism: Rattus norvegicus (Rat) |
0.14 µM [Ki] | ||
Target ID: P47747 Gene ID: NA Gene Symbol: HRH2 Target Organism: Cavia porcellus (Guinea pig) |
0.19 µM [Ki] | ||
Target ID: P25021 Gene ID: 3274.0 Gene Symbol: HRH2 Target Organism: Homo sapiens (Human) |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | ZANTAC 150 Approved UseZANTAC® (ranitidine hydrochloride) Tablets and Injection are indicated for the treatment of duodenal ulcer, benign gastric ulcer, reflux esophagitis, post-operative peptic ulcer, Zollinger-Ellison Syndrome, and other conditions where reduction of gastric secretion
and acid output is desirable. These include the following:
• the treatment of nonsteroidal anti-inflammatory drug (NSAID)- induced lesions, both ulcers and erosions, and their gastrointestinal (GI) symptoms and the prevention of their recurrence;
• the prophylaxis of GI hemorrhage from stress ulceration in seriously ill patients;
• the prophylaxis of recurrent hemorrhage from bleeding ulcers;
• the prevention of Acid Aspiration Syndrome from general anaesthesia in patients considered to be at risk for this, including obstetrical patients in labour, and obese patients.
In addition, ZANTAC® is indicated for the prophylaxis and maintenance treatment of duodenal or benign gastric ulcer in patients with a history of recurrent ulceration. Launch Date4.23964803E11 |
|||
| Primary | ZANTAC 150 Approved UseZANTAC® (ranitidine hydrochloride) Tablets and Injection are indicated for the treatment of duodenal ulcer, benign gastric ulcer, reflux esophagitis, post-operative peptic ulcer, Zollinger-Ellison Syndrome, and other conditions where reduction of gastric secretion
and acid output is desirable. These include the following:
• the treatment of nonsteroidal anti-inflammatory drug (NSAID)- induced lesions, both ulcers and erosions, and their gastrointestinal (GI) symptoms and the prevention of their recurrence;
• the prophylaxis of GI hemorrhage from stress ulceration in seriously ill patients;
• the prophylaxis of recurrent hemorrhage from bleeding ulcers;
• the prevention of Acid Aspiration Syndrome from general anaesthesia in patients considered to be at risk for this, including obstetrical patients in labour, and obese patients.
In addition, ZANTAC® is indicated for the prophylaxis and maintenance treatment of duodenal or benign gastric ulcer in patients with a history of recurrent ulceration. Launch Date4.23964803E11 |
|||
| Primary | ZANTAC 150 Approved UseZANTAC® (ranitidine hydrochloride) Tablets and Injection are indicated for the treatment of duodenal ulcer, benign gastric ulcer, reflux esophagitis, post-operative peptic ulcer, Zollinger-Ellison Syndrome, and other conditions where reduction of gastric secretion
and acid output is desirable. These include the following:
• the treatment of nonsteroidal anti-inflammatory drug (NSAID)- induced lesions, both ulcers and erosions, and their gastrointestinal (GI) symptoms and the prevention of their recurrence;
• the prophylaxis of GI hemorrhage from stress ulceration in seriously ill patients;
• the prophylaxis of recurrent hemorrhage from bleeding ulcers;
• the prevention of Acid Aspiration Syndrome from general anaesthesia in patients considered to be at risk for this, including obstetrical patients in labour, and obese patients.
In addition, ZANTAC® is indicated for the prophylaxis and maintenance treatment of duodenal or benign gastric ulcer in patients with a history of recurrent ulceration. Launch Date4.23964803E11 |
|||
| Primary | ZANTAC 150 Approved UseZANTAC® (ranitidine hydrochloride) Tablets and Injection are indicated for the treatment of duodenal ulcer, benign gastric ulcer, reflux esophagitis, post-operative peptic ulcer, Zollinger-Ellison Syndrome, and other conditions where reduction of gastric secretion
and acid output is desirable. These include the following:
• the treatment of nonsteroidal anti-inflammatory drug (NSAID)- induced lesions, both ulcers and erosions, and their gastrointestinal (GI) symptoms and the prevention of their recurrence;
• the prophylaxis of GI hemorrhage from stress ulceration in seriously ill patients;
• the prophylaxis of recurrent hemorrhage from bleeding ulcers;
• the prevention of Acid Aspiration Syndrome from general anaesthesia in patients considered to be at risk for this, including obstetrical patients in labour, and obese patients.
In addition, ZANTAC® is indicated for the prophylaxis and maintenance treatment of duodenal or benign gastric ulcer in patients with a history of recurrent ulceration. Launch Date4.23964803E11 |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
440 ng/mL |
150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered: |
RANITIDINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
948.6 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6094785/ |
80 mg single, oral dose: 80 mg route of administration: Oral experiment type: SINGLE co-administered: |
RANITIDINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
1.69 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6094785/ |
80 mg single, oral dose: 80 mg route of administration: Oral experiment type: SINGLE co-administered: |
RANITIDINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
2.5 h |
150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered: |
RANITIDINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Funbound
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
85% |
150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered: |
RANITIDINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Doses
| Dose | Population | Adverse events |
|---|---|---|
100 mg single, oral Highest studied dose |
healthy, adult n = 136 Health Status: healthy Age Group: adult Sex: M+F Population Size: 136 Sources: |
|
1500 mg single, oral Overdose Dose: 1500 mg Route: oral Route: single Dose: 1500 mg Sources: |
unknown, children n = 517 Health Status: unknown Age Group: children Sex: unknown Population Size: 517 Sources: |
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
Drug as perpetrator
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
| no | ||||
| no | ||||
| no | no (co-administration study) Comment: Ranitidine has no effect on midazolam exposure |
|||
| weak [IC50 290 uM] | ||||
| weak | ||||
| yes [IC50 114 uM] | ||||
| yes [IC50 18.9 uM] | ||||
| yes [IC50 28 uM] | ||||
| yes [Ki 25 uM] |
Drug as victim
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
| major | ||||
| minor | ||||
| minor | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| yes | ||||
| yes | ||||
| yes | ||||
| yes | ||||
| yes |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Histamine H2 antagonists and the nervous system. | 1985 Dec |
|
| Comparison of ranitidine and high-dose antacid in the treatment of prepyloric or duodenal ulcer. A double-blind controlled trial. | 1985 Jan |
|
| Bradycardia and neurologic disorders associated with ranitidine in a child. | 1985 May |
|
| Depression associated with ranitidine. | 1986 Jul |
|
| Myofascial headache. Exacerbation of symptoms due to diflunisal and ranitidine therapy. A case report. | 1987 Aug |
|
| Fatal renal and hepatic toxicity after treatment with diltiazem. | 1987 Nov 14 |
|
| Famotidine-associated mental confusion in elderly patients. | 1988 Dec |
|
| First-degree atrioventricular block in a young duodenal ulcer patient treated with a standard oral dose of ranitidine. | 1988 Jul |
|
| Ranitidine-induced confusion with concomitant morphine. | 1988 Nov |
|
| A dog model for acetaminophen-induced fulminant hepatic failure. | 1989 Feb |
|
| Mechanism of ranitidine associated anemia. | 1989 Jun |
|
| Ranitidine-induced chest pain. | 1989 Mar |
|
| Effects of histamine H2-receptor blockade on the cardiovascular reflex response to lower-body negative pressure in man. | 1990 May |
|
| Seizures during concomitant treatment with theophylline and ranitidine: a case report. | 1990 Oct-Dec |
|
| Effects of antihistaminics on locomotor activity in mice. Comparison with opiate and amphetamine-induced hyperactivity. | 1991 |
|
| Ranitidine and depression. | 1991 Sep |
|
| Intrahepatic cholestatic jaundice related to administration of ranitidine. A case report with histologic and ultramicroscopic study. | 2004 Dec |
|
| Evaluation of fresh and cryopreserved hepatocytes as in vitro drug metabolism tools for the prediction of metabolic clearance. | 2004 Nov |
|
| Histamine H2-receptor antagonist ranitidine protects against neural death induced by oxygen-glucose deprivation. | 2004 Oct |
|
| Carrier-mediated uptake of H2-receptor antagonists by the rat choroid plexus: involvement of rat organic anion transporter 3. | 2004 Sep |
|
| Switching of H(2)-Receptor Antagonists to Over-the-Counter Status in Finland : Implications for Consumption and Adverse Effects. | 2005 |
|
| Lethal cardiomyopathy in epidermolysis bullosa associated with amitriptyline. | 2005 Aug |
|
| Differential substrate and inhibitory activities of ranitidine and famotidine toward human organic cation transporter 1 (hOCT1; SLC22A1), hOCT2 (SLC22A2), and hOCT3 (SLC22A3). | 2005 Dec |
|
| Role of histamine in airway remodeling of asthmatic guinea pig. | 2005 Dec 25 |
|
| Drug specificity and intestinal membrane localization of human organic cation transporters (OCT). | 2005 Dec 5 |
|
| Weak inhibitors protect cholinesterases from strong inhibitors (paraoxon): in vitro effect of ranitidine. | 2005 Jan-Feb |
|
| Laryngopharyngeal reflux: prospective cohort study evaluating optimal dose of proton-pump inhibitor therapy and pretherapy predictors of response. | 2005 Jul |
|
| Mechanisms of action of leptin in preventing gastric ulcer. | 2005 Jul 21 |
|
| Prediction of genotoxicity of chemical compounds by statistical learning methods. | 2005 Jun |
|
| Intracerebroventricular effects of histaminergic agents on morphine-induced anxiolysis in the elevated plus-maze in rats. | 2005 Nov |
|
| Excitatory effect of histamine on neuronal activity of rat globus pallidus by activation of H2 receptors in vitro. | 2005 Nov |
|
| Weak inhibitors protect cholinesterases from strong inhibitors (paraoxon): in vitro effect of tiapride. | 2005 Nov-Dec |
|
| A species difference in the transport activities of H2 receptor antagonists by rat and human renal organic anion and cation transporters. | 2005 Oct |
|
| Antisecretory and antiulcer activity of Asparagus racemosus Willd. against indomethacin plus phyloric ligation-induced gastric ulcer in rats. | 2006 |
|
| Cimetidine induces interleukin-18 production through H2-agonist activity in monocytes. | 2006 Aug |
|
| Inlet patch of gastric mucosa in upper esophagus causing chronic cough and vocal cord dysfunction. | 2006 Jan |
|
| Attenuation of indomethacin- and HCl/ethanol-induced oxidative gastric mucosa damage in rats by kolaviron, a natural biflavonoid of Garcinia kola seed. | 2006 Jan |
|
| Gastroprotective and antioxidant effects of usnic acid on indomethacin-induced gastric ulcer in rats. | 2006 Jan 3 |
|
| Is the monkey an appropriate animal model to examine drug-drug interactions involving renal clearance? Effect of probenecid on the renal elimination of H2 receptor antagonists. | 2006 Mar |
|
| Coagulation-dependent gene expression and liver injury in rats given lipopolysaccharide with ranitidine but not with famotidine. | 2006 May |
|
| Novel role of famotidine in downregulation of matrix metalloproteinase-9 during protection of ethanol-induced acute gastric ulcer. | 2007 Jul 15 |
|
| Gastroprotective and antioxidant effects of amiodarone on indomethacin-induced gastric ulcers in rats. | 2007 Nov |
|
| The role of tumor necrosis factor alpha in lipopolysaccharide/ranitidine-induced inflammatory liver injury. | 2007 Nov |
|
| Gastroprotective and antioxidant effects of montelukast on indomethacin-induced gastric ulcer in rats. | 2007 Sep |
|
| Gastroprotective and anti-oxidative properties of ascorbic acid on indomethacin-induced gastric injuries in rats. | 2008 Winter |
|
| Synergistic drug-cytokine induction of hepatocellular death as an in vitro approach for the study of inflammation-associated idiosyncratic drug hepatotoxicity. | 2009 Jun 15 |
|
| Protective effect of histamine H2 receptor antagonist ranitidine against rotenone-induced apoptosis. | 2009 Nov |
|
| Drug-induced aseptic meningitis, sensorineural hearing loss and vestibulopaty. | 2010 Sep |
|
| Hepatoprotective, antinociceptive and antioxidant activities of cimetidine, ranitidine and famotidine as histamine H2 receptor antagonists. | 2011 Feb |
|
| A correlation between the in vitro drug toxicity of drugs to cell lines that express human P450s and their propensity to cause liver injury in humans. | 2014 Jan |
Patents
Sample Use Guides
In Vivo Use Guide
Curator's Comment:: In some hospitalized patients with pathological hypersecretory conditions or intractable duodenal ulcers, or in patients unable to take oral medication, ZANTAC® may be administered parenterally (intramuscular or intravenous injections): 50 mg (2 mL) every six to eight hours.
150 mg twice daily (tablets or syrup)
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Jun 25 20:53:59 UTC 2021
by
admin
on
Fri Jun 25 20:53:59 UTC 2021
|
| Record UNII |
BK76465IHM
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C29702
Created by
admin on Fri Jun 25 20:54:00 UTC 2021 , Edited by admin on Fri Jun 25 20:54:00 UTC 2021
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
Ranitidine hydrochloride
Created by
admin on Fri Jun 25 20:54:00 UTC 2021 , Edited by admin on Fri Jun 25 20:54:00 UTC 2021
|
PRIMARY | |||
|
BK76465IHM
Created by
admin on Fri Jun 25 20:54:00 UTC 2021 , Edited by admin on Fri Jun 25 20:54:00 UTC 2021
|
PRIMARY | |||
|
203136
Created by
admin on Fri Jun 25 20:54:00 UTC 2021 , Edited by admin on Fri Jun 25 20:54:00 UTC 2021
|
PRIMARY | RxNorm | ||
|
M9498
Created by
admin on Fri Jun 25 20:54:00 UTC 2021 , Edited by admin on Fri Jun 25 20:54:00 UTC 2021
|
PRIMARY | Merck Index | ||
|
47909
Created by
admin on Fri Jun 25 20:54:00 UTC 2021 , Edited by admin on Fri Jun 25 20:54:00 UTC 2021
|
PRIMARY | |||
|
C66506
Created by
admin on Fri Jun 25 20:54:00 UTC 2021 , Edited by admin on Fri Jun 25 20:54:00 UTC 2021
|
PRIMARY | |||
|
1598405
Created by
admin on Fri Jun 25 20:54:00 UTC 2021 , Edited by admin on Fri Jun 25 20:54:00 UTC 2021
|
PRIMARY | USP-RS | ||
|
266-333-0
Created by
admin on Fri Jun 25 20:54:00 UTC 2021 , Edited by admin on Fri Jun 25 20:54:00 UTC 2021
|
PRIMARY | |||
|
CHEMBL1790041
Created by
admin on Fri Jun 25 20:54:00 UTC 2021 , Edited by admin on Fri Jun 25 20:54:00 UTC 2021
|
PRIMARY | |||
|
SUB04203MIG
Created by
admin on Fri Jun 25 20:54:00 UTC 2021 , Edited by admin on Fri Jun 25 20:54:00 UTC 2021
|
PRIMARY | |||
|
66357-59-3
Created by
admin on Fri Jun 25 20:54:00 UTC 2021 , Edited by admin on Fri Jun 25 20:54:00 UTC 2021
|
PRIMARY | |||
|
DBSALT000487
Created by
admin on Fri Jun 25 20:54:00 UTC 2021 , Edited by admin on Fri Jun 25 20:54:00 UTC 2021
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE | |||
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (TITRATION)
EP
|
||
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (HPLC)
USP
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
IMPURITY -> PARENT |
UNSPECIFIED
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
UNSPECIFIED
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
UNSPECIFIED
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
For the calculation of contents, multiply the peak areas by 0.2
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
UNSPECIFIED
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
UNSPECIFIED
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
UNSPECIFIED
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
UNSPECIFIED
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |